IKT vs INVA

Innoviva, Inc.

(INVA) offers the better valuation at 6. 8x trailing P/E (6. 3x forward), making it the more compelling value choice. Analysts rate Innoviva, Inc. (INVA) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Innoviva, Inc.

(INVA) delivered a total return of +78. 1%, compared to -95. 3% for Inhibikase Therapeutics, Inc. (IKT). Over 10 years, the gap is even starker: INVA returned +105. 3% versus IKT's -97. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Innoviva, Inc.

(INVA) is the lower-risk stock at 0. 12β versus Inhibikase Therapeutics, Inc. 's 1. 98β — meaning IKT is approximately 1532% more volatile than INVA relative to the S&P 500.

On earnings-per-share growth, the picture is similar: Innoviva, Inc.

grew EPS 816. 7% year-over-year, compared to 57. 8% for Inhibikase Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Innoviva, Inc.

(INVA) is the more profitable company, earning 63. 8% net margin versus 0. 0% for Inhibikase Therapeutics, Inc. — meaning it keeps 63. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INVA leads at 38. 5% versus 0. 0% for IKT. At the gross margin level — before operating expenses — INVA leads at 72. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for IKT: 139.

5% to $4. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Innoviva, Inc.

(INVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 12), +105. 3% 10Y return). Inhibikase Therapeutics, Inc. (IKT) carries a higher beta of 1. 98 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (INVA: +105. 3%, IKT: -97. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: IKT is a small-cap quality compounder stock; INVA is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.